A Novel Approach for Determining the Critical Quality Attributes of Mesenchymal Stem Cells by Specifying Cell Population With Replication Potential
Stem Cells Translational Medicine · 17.03.2023 · 12 (3) · 169-182
DOI: 10.1093/stcltm/szad005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 14.03.2023. Verfasst von Takako Yamamoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED.
Abstract (Originalsprache)
We introduce a novel approach to determine the critical quality attributes (CQAs) of mesenchymal stem cells (MSCs) expected to exert immunosuppressive effects. MSCs retained homeostatic replication potentials, such as sustainable growth and consistent cell morphology as a population, in early passages, but lost them in late passages. Characteristic surface markers of MSCs (ie, CD73, CD90, and CD105) were no longer expressed at 2 weeks after subcutaneous transplantation into NOG mice when MSCs from late passages were transplanted, but not when MSCs from early passages were transplanted, suggesting that the biological effects of the MSCs differed according to the timing of cell harvesting and highlighting the importance of specifying MSCs that retained homeostatic features to define the CQAs. The homeostatic features of MSCs related to the balance of the redox system, nutrient requirements, and mitochondrial function were also observed until a certain passage. Therefore, we could define the CQAs of MSCs related to manufacturing by selecting process parameters (PPs) underlying the homeostatic features of MSCs and measuring these PPs quantitatively to specify the cell population with homeostatic features by limiting the passage number. The validity of the PPs stipulated in our pilot study was verified using an SKG murine arthritis model, and critical PPs (CPPs) were then selected among the PPs. Thus, CQAs related to manufacturing in the developmental phase could be defined by the CPPs in this manner, and the concept of CQAs could be refined continuously toward commercial manufacturing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- R&D Center for Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
- Novartis Pharma KK, Tokyo, Japan.
- Shimadzu Corp., Kyoto, Japan.
- Graduate School of Engineering, Osaka University, Osaka, Japan.
ORCID-Profile: Takako Yamamoto
Förderung
- AMED
Zitieren
APA
Yamamoto, T., Arita, M., Tamura, T., Saito, M., Katayama, H., Kuroda, H., Suzuki, T., & Kawamata, S. (2023). A Novel Approach for Determining the Critical Quality Attributes of Mesenchymal Stem Cells by Specifying Cell Population With Replication Potential. Stem Cells Translational Medicine, 12(3), 169-182. https://doi.org/10.1093/stcltm/szad005
Vancouver
Yamamoto T, Arita M, Tamura T, Saito M, Katayama H, Kuroda H, et al. A Novel Approach for Determining the Critical Quality Attributes of Mesenchymal Stem Cells by Specifying Cell Population With Replication Potential. Stem Cells Translational Medicine. 2023;12(3):169-182. doi:10.1093/stcltm/szad005
BibTeX
@article{Yamamoto2023,
author = {Yamamoto, Takako and Arita, Mao and Tamura, Takashi and Saito, Miho and Katayama, Hirohito and Kuroda, Hirotaka and Suzuki, Takashi and Kawamata, Shin},
title = {A Novel Approach for Determining the Critical Quality Attributes of Mesenchymal Stem Cells by Specifying Cell Population With Replication Potential},
journal = {Stem Cells Translational Medicine},
year = {2023},
volume = {12},
number = {3},
pages = {169--182},
doi = {10.1093/stcltm/szad005}
}
EUVIMED